Most breast cancers are categorized as estrogen-receptor positive, which means they are hormone sensitive and may need estrogen to grow. Patients with this type of cancer often respond favorably to aromatase inhibitors, like tamoxifen
, which cause cell death by preventing estrogen from reaching the cancerous cells. Over time, the disease often becomes resistant to estrogen deprivation from the drugs, making treatment options more limited.
New findings from the AACR Annual Meeting identified a pair of proteins that could play a crucial role in restoring treatment sensitivity to these resistant cancerous cells—possibly leading to more treatment options in the future.